Splenic myeloid metaplasia in warm autoimmune hemolytic anemia (wAIHA): a retrospective study.
- Author:
Víctor Manuel ANGUIANO-ÁLVAREZ
1
;
Alonso HERNÁNDEZ-COMPANY
;
Nashla HAMDAN-PÉREZ
;
Daniel MONTANTE-M
;
Diego A ZÚÑIGA-TAMAYO
;
Sergio RODRÍGUEZ-RODRÍGUEZ
;
Alan POMERANTZ
;
Elena J TUNA-AGUILAR
Author Information
- Publication Type:Original Article
- Keywords: Warm autoimmune hemolytic anemia; Splenic myeloid metaplasia; Splenic-congestion; Extramedullary hematopoiesis
- MeSH: Anemia, Hemolytic, Autoimmune*; Antibodies; Hematopoiesis, Extramedullary; Humans; Platelet Count; Primary Myelofibrosis*; Protective Factors; Retrospective Studies*; Risk Factors; Spleen; Splenectomy; Steroids; Tertiary Care Centers
- From:Blood Research 2018;53(1):35-40
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND: Splenic myeloid metaplasia (SMM) is a kind of extramedullary hematopoiesis, whereas its clinical significance in wAIHA remains unclear. The aim of this study is evaluating the frequency and clinical characteristics of SMM, compared with splenic-congestion (SC). METHODS: We included patients with wAIHA treated in a Mexican tertiary hospital between January 1992 and December 2015. All patients received steroids as first-line treatment and splenectomy as second-line treatment. RESULTS: Among the thirty-six splenectomized patients, 15 (41.6%) and 21 (58.4%) were diagnosed as SMM and SC, respectively. No differences were found in clinical characteristics between two groups. SMM patients showed lower platelet count (147×109/L vs. 240×109/L, P=0.02) and higher presence of anti-dsDNA antibodies (40% vs. 4.7%, P=0.01) than SC patients. Although the complete response (CR) rate with first-line treatment was lower in SMM patients (13.3% vs. 47.6%; P=0.04), post-splenectomy median disease-free-survival (DFS) was longer (16.2 mo vs. 5.1 mo; P=0.19). Univariate/multivariate analysis showed that achieving CR during first-line treatment (OR 0.3, 95% CI: 0.03–0.94, P=0.03) and higher platelet count (OR 0.99, 95% CI: 0.98–0.99, P=0.03) were protective factors for SMM; and anti-dsDNA titer higher than 9.6 IU/dL was a risk factor for SMM (OR 2.76, 95% CI: 1.48–5.14, P < 0.001). CONCLUSION: The wAIHA patients with SMM have different biological profiles with those without SMM. This study is the first trial evaluating the significance of histopathological spleen findings and their association with rheumatologic profile.
